FTC Approves Modified Final Order Addressing Competitive Concerns about Hikma Pharmaceuticals PLC’s Acquisition of Roxane

The Federal Trade Commission has approved a modified final order settling charges that Hikma Pharmaceuticals PLC’s $2 billion acquisition of  Roxane Laboratories Inc. and Boehringer Ingelheim Roxane, Inc. from Boehringer Ingelheim Corporation would likely be anticompetitive.

Under the terms of the order, Hikma is required to divest to Pennsylvania-based Renaissance Pharma, Inc. the rights and assets for two generic drugs, prednisone tablets and lithium carbonate capsules. The order also requires Hikma to relinquish to its drug development partner, India-based Unimark Remedies Ltd., the rights to market flecainide acetate tablets in the United States and to divest its equity interest in Unimark. The order was modified to extend the deadline for divestiture by 20 days.

The Commission vote to approve the modified final order was 3-0. (FTC File No. 151 0198; the staff contact is Jacqueline Mendel, Bureau of Competition, 202-326-2603)                                                                                                                           

The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow us on Twitter, read our blogs and subscribe to press releases for the latest FTC news and resources.